Anti-TNF-α-induced psoriasis: Case report of an unusual adverse event [1]

International Journal of Dermatology

Volumn 45, Issue 8, 2006, Pages 982-983

  Aslanidis, Spyros ^a   Pyrpasopoulou, Athina ^a   Leontsini, Maria ^a   Zamboulis, Chryssanthos ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ELBOW; FEMALE; HISTOPATHOLOGY; HUMAN; INJECTION SITE ERYTHEMA; JOINT DESTRUCTION; LETTER; LONG TERM CARE; NECK; PRURITUS; PSORIASIS; RASH; RHEUMATOID ARTHRITIS; SCALP; SCORING SYSTEM; STEROID THERAPY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746597858     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.03041.x     Document Type: Letter

References (9)

1. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005; 140: 195-204.
2. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept psoriasis study group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
3. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 2001; 357: 1842-1847.
4. Mease PJ, Antoni CE. Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 2005; 64: Ii78-82.
5. Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
6. Bongartz T, Harle P, Friedrich S, et al. Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 2005; 52: 280-282.
7. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513-2518.
8. Gordon KB, Bonish BK, Patel T, et al. The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in prosiatic plaques. Br J Dermatol 2005; 153: 945-953.
9. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalmumab. Arthritis Rheum 2004; 50: 1690-1692.